News

MJFF Offers Free Resources About ‘Off’ Time

The Michael J. Fox Foundation (MJFF) has released a new suite of free educational resources that focuses on so-called “off” periods when Parkinson’s disease symptoms reappear or worsen as medications wear off. These new resources, available at michaeljfox.org/off, offer patients and their families tips for managing “off” time,…

Antioxidant Urate Fails to Slow Early Disease Progression

The antioxidant urate failed to slow Parkinson’s disease progression in newly diagnosed patients over two years, according to data from a Phase 3 clinical trial. “While our study did not rule out a protective effect of urate in Parkinson’s, it clearly showed that increasing urate did not slow disease…

Genetic Testing Costly, Hard to Access, Survey Shows

High prices, lack of access, and long waiting times are major barriers to people who want to undergo genetic testing for Parkinson’s disease, according to a survey by the International Parkinson and Movement Disorder Society (MDS). Survey results will be presented at the MDS Virtual Congress 2021, held…

No Need for Nausea Treatment for Most Patients on Kynmobi

The majority of Parkinson’s patients given Sunovion‘s Kynmobi (apomorphine hydrochloride) for “off” episodes during Phase 3 clinical trials did not require additional treatment for vomiting or nausea, the company said. Indeed, an analysis found that nearly 90% of participants reached the optimal dose of Kynmobi in trials without…

Study: NSAIDs Seem to Have No Effect on Parkinson’s Incidence

The use of non-steroidal anti-inflammatory drugs (NSAIDs) seems to have no effect on the incidence of Parkinson’s disease, according to a large retrospective Norwegian study. Researchers focused on the NSAIDs prescribed most in Norway: diclofenac, ibuprofen, and naproxen. In the study “NSAID use is not associated with Parkinson’s…

Small Molecules, STARs Treat Cell Models of GBA1-linked Parkinson’s

Two investigational small molecules known as GT-02287 and GT-02329 lowered toxic protein levels in patient-derived cell models of Parkinson’s disease associated with a mutation in GBA1, their developer, Gain Therapeutics, announced. Gain is planning additional preclinical studies this year that could support applications to regulatory agencies allowing the compounds to…

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums